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Abstract. Emerging drug resistance in epithelial ovarian 
cancer (EOC) thwarted progress in platinum-based chemo-
therapy, resulting in increased mortality, morbidity and 
healthcare costs. The aim of this study was to detect the 
responses induced by chemotherapy at protein and metabo-
lite levels, and to search for new plasma markers that can 
predict resistance to platinum-based chemotherapy in EOC 
patients, leading to improved clinical response rates. Serum 
samples were collected and subjected to proteomic relative 
quantitation analysis and metabolomic analysis. Differentially 
expressed proteins and metabolites were subjected to bioin-
formatics and statistical analysis. Proteins that played a 
key role in platinum resistance were validated by western 
blotting and enzyme-linked immunosorbent assay (ELISA). 
Metabolites that were the main contributors to the groups 
and closely with clinical characteristics were identified based 
on the database using nuclear magnetic resonance (NMR). 
In total, 248 proteins from two independent experiments 
were identified using isobaric tags for relative and absolute 
quantitation (iTRAQ)-based quantitative proteomic approach. 
Among them, FN1, SERPINA1, GPX3 and ORM1 were chosen 
for western blotting and ELISA validation. Platinum resis-
tance likely associated with differentially expressed proteins 
and FN1, SERPINA1 and ORM1 may play a positive role in 
chemotherapy. HPLC-MS analysis of four groups revealed a 
total of 25,800 metabolic features, of which six compounds 
were chosen for candidate biomarkers and identified based on 
the database using NMR. The metabolic signatures of normal 
control (NC), platinum-sensitive (PTS) and platinum-resis-
tant (PTR) groups were clearly separated from each other. 
Those findings may provide theoretical clues for the prediction 
of chemotherapeutic response and reverse of drug resistance, 
even lead to novel targets for therapeutic intervention.
Introduction
Ovarian cancer is the fifth leading cause of cancer deaths in 
women and has the highest overall mortality rate and poor 
5-year survival. More than 90% of ovarian cancer cases are 
epithelial ovarian cancer (EOC), which represents a series of 
etiologically and molecularly distinct disease. Although early 
diagnosis and therapy are considered to be the most effective 
methods to improve the outcome of patients with any cancer, 
the majority of EOC patients often do not manifest clinical 
symptoms and receive medical intervention when their tumor 
cells have disseminated to the peritoneal cavity. Currently, 
the standard therapy for EOC is surgical resection followed 
by postoperative chemotherapy with carboplatin and pacli-
taxel (PTX). Despite initial responsiveness to cisplatin-based 
chemotherapy, surgical and chemotherapy is far from satis-
factory and most patients eventually develop drug-resistant 
tumors and succumb to the recurrent disease. This is why the 
majority of EOC patients with advanced disease relapse within 
5 years, and little progress has been made in improving overall 
survival rates. Previous studies have proposed numerous 
factors to influence drug‑resistance, such as ATP‑dependent 
efflux pumps, extracellular microenvironment, DNA repair 
mechanism, modification of the drug target, drug-induced 
cytotoxicity, disruptions in apoptotic signaling pathways and 
changes in the expression of protein associated with tumor 
resistance (1,2). Cisplatin has been used to treat various 
cancers primarily by causing DNA damage and has been 
accepted worldwide as a first‑line anticancer drug for EOC 
chemotherapy. In this regard, to identify those patients who 
have potential recurrence and to overcome chemoresistance 
and therefore improving patient outcome are the serious chal-
lenges in the management of EOC patients. Nevertheless, none 
of the identified biomarkers for drug resistance have been 
proven acceptable for routine clinical use. Hence, identifica-
tion of clinical reliable biomarkers has come to the forefront 
of investigation. Moreover, if a non-invasive but sensitive 
blood assay that can monitor responses to chemotherapy was 
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available, it would be invaluable for guiding chemotherapy and 
greatly improving the overall survival rate of EOC patients.
Mass spectrometry (MS) is an important high-throughput, 
industrially stable, information‑rich technique for profiling small 
molecular compounds and is widely used to assess potential 
diagnostic and prognostic biomarkers. We applied isobaric tags 
for relative and absolute quantitation (iTRAQ)-based quantita-
tive proteomic approach (Fig. 1A) and HPLC‑micrOTOF‑Q Ⅱ 
high-resolution mass spectro-meter-based metabolic analysis 
to compare and identify proteins and metabolites with differ-
ential profile in normal control (NC) group, benign ovarian 
cyst (BOC), platinum-sensitive (PTS)  and platinum-resis-
tant (PTR) cohort of serum samples. The emergence of resistance 
to platinum-based therapy is the main clinical endpoint of this 
experiment. iTRAQ proteomic analysis that combines 2D-LC 
and MALDI-TOF-MS/MS is an established technique in which 
total proteins are enzymatically digested into a large array of 
small peptide fragments and then directly analyzed by liquid 
chromatography-mass spectro-metry (LC-MS). A total of 
64 proteins with different expression levels were identified. 
In the list of differentially identified proteins via this method, 
most of these proteins were in accordance with the previously 
published literatures and associated with cancers. In addition, 
to further explore the new biomarkers predicting the responses 
to cisplatin, four of these proteins (FN1, SERPINA1, ORM1 and 
GPX3) were confirmed in a large patient cohort using western 
blotting and commercial enzyme-linked immunosorbent 
assay (ELISA), respectively. Moreover, HPLC‑micrOTOF‑Q Ⅱ 
MS coupled with multivariate analysis was utilized, good sepa-
rations were obtained for PTR, PTS vs. health controls. Finally, 
six substances with low molecular weight were identified based 
on the database using nuclear magnetic resonance (NMR). 
Receiver operating characteristic (ROC) curve analysis was 
then used to elucidate the potential power of FN1, SERPINA1, 
ORM1 and six small molecular metabolites for discriminating 
between the PTS and PTR group. The findings of this study 
are expected to reveal new proteins and metabolites related 
to platinum resistance and to provide candidate biomarkers 
to predict clinical response to chemotherapy. However, we do 
need an effective serum marker to predict the patients who have 
no response to cisplatin chemotherapy and will progress or 
recur during or after chemotherapy that cannot be easily judged 
from ultrasound or CT scan. This prediction is fundamental 
since patients that are resistant might benefit from a different 
combinational chemotherapy.
Materials and methods
Human serum samples. After Institutional Review Board 
approval (Ethics Committees of the Affiliated Tumor Hospital 
of Guangxi Medical University, Nanning, China), we obtained 
specimens (Table I) between September 1998 and March 2013, 
including EOC and BOC specimens. EOC cases were assigned 
to the PTR and PTS group. The FIGO classification was used 
for clinical staging, and the Gynecologic Oncology Group 
criteria were used for histological grading. NC blood samples 
were voluntarily donated by healthy individuals. Patients were 
eligible to participate in this trial if they had a pathologically 
confirmed diagnosis of BOC or EOC. After giving informed 
consent, serum samples were collected by clean venipuncture, 
centrifuged for 10 min at 3,000 x g at 4˚C and stored at ‑80˚C 
until further analysis.
Chemicals and reagents. The iTRAQ™ Reagent kit and 
mass calibration standards were purchased from Applied 
Biosystems (Bedford, MA, USA). Sequencing grade trypsin 
was obtained from Promega (Madison, WI, USA). Amicon 
Ultra-15 Certifugal Filter Units (3 kDa) were purchased 
from EMD Millipore (Billerica, MA, USA). All the solvents 
and chemicals used in this experiment were of LC-MS or 
analytical grade. HPLC grade water and acetonitrile (ACN) 
were purchased from Merck KGaA (Darmstadt, Germany). 
BCA assay kit was purchased from Pierce Biotechnology, 
Inc. (Rockford, IL, USA). Methyl methanethiosulfo-
nate (MMTS) and methanol were obtained from Thermo 
Fisher Scientific (Rockford, IL, USA). Triethylammonium 
bicarbonate (TEAB), trifluoroacetic acid (TFA), formic acid 
and α-cyano-4-hydroxycinnamic acid (CHCA) were all 
obtained from Sigma (St. Louis, MO, USA).
Proteomic analysis
Depletion of high abundant proteins. Pooled serum samples 
were depleted of the 14 most highly abundant proteins using 
antibody‑based depletion with Human 14 Multiple Affinity 
Removal System (MARS Hu‑14; Agilent Technologies, Inc., 
Palo Alto, CA, USA), according to the manufacturer's instruc-
tions. Crude serum samples were thawed on ice. Equal amounts 
of blood (20 µl) from 10 individuals in each group were pooled. 
Thereafter, MARS Hu‑14 column was used to deplete specific 
14 high-abundant proteins ~94% of total protein mass from 
human serum (Fig. 1B). The total protein concentrations of the 
depleted sera were determined using the BCA Protein Assay 
Reagent Kit (Pierce Biotechnology, Inc.) (Fig. 1C).
iTRAQ labeling. Prior to iTRAQ analysis, aliquots of 100 µg 
protein from each of the four sample pools were reduced using 
dissolution buffer (0.5 M TEAB) to a volume of 20 µl. To each 
of the four pools, 1 µl denaturant (2% SDS) and 2 µl reducing 
reagent [50 mM tris(2-carboxyethyl)phosphine] were added. 
Each pool was incubated at 60˚C for 1 h. Cysteines were stopped 
by adding 1 µl cystine-blocking reagent (200 mM MMTS in 
isopropanol), and samples were incubated for additional 10 min at 
room temperature. The samples were digested with Sequencing 
Grade Modified Trypsin (Promega) at a protein‑to‑trypsin ratio 
of 30:1, at 37˚C overnight. After that, peptides from each of the 
four depleted serum pools were labeled with 8-plex iTRAQ 
reagents (AB SCIEX, Foster City, CA, USA) according to the 
manufacturer's instructions. The labels were applied in the 
following order: NC pool (113 Da), BOC pool (114 Da), PTS 
pool (115 Da); PTR pool (116 Da), so as to run the same sample 
in duplicate in each run. The four labeled samples were then 
evaporated to a volume of roughly 30 µl using a SpeedVac 
Concentrator and combined as a mixture followed by cleaning 
up by a strong cation exchange (SCX) column.
2D‑LC‑ESI‑MS/MS. The combined peptide sample 
was subjected to SCX chromatography employing a 
PolySulfoethyl A column (2.1x200 nm; PolyLC, Inc., Columbia, 
MD, USA), on a high‑pressure LC‑pump (1200 series; Agilent 
Technologies, Inc.). The mixed sample was diluted in 10 mM 
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Table I. Clinical characteristics of 40 cases of samples used in screening, 129 cases in validating and 132 samples in comparing 
metabolomic profiles between NC, BOC, PTS and PTR groups.
Clinical characteristics NC BOC PTS PTR P-value
iTRAQ (n=40)
  No. of patients 10 10 10 10 -
  iTRAQ-labeled sample 113 (run 1) 114 (run 1) 115 (run 1) 116 (run 1) -
 117 (run 2) 118 (run 2) 119 (run 2) 121 (run 2) -
  Age (years) (mean ± SD) 39.80±5.53 44.1±18.11 47.21±12.64 44.85±16.17 -
  Histological type     
    Serous - 6/10   4/10   6/10 -
    Mucinous - 2/10   2/10   1/10 -
    Other - 2/10   4/10   3/10 -
  FIGO stage     
    I‑Ⅱ ‑ ‑   3/10   3/10 ‑
    Ⅲ‑Ⅳ ‑ ‑   7/10   7/10 ‑
  Tumor grade     
    Well-differentiated - -   1/10   2/10 -
    Moderately-differentiated - -   1/10   1/10 -
    Poorly-differentiated - -   8/10   7/10 -
ELISA (n=129)
  No. of patients 33 - 52 44 -
  Age (years) (mean ± SD) 39.71±10.05 - 46.33±10.65 47.08±10.85 -
  Histological type     
    Serous - - 26/52 17/44 -
    Mucinous - -   7/52   6/44 -
    Other - - 19/52 21/44 -
  TNM stage     
    I‑Ⅱ ‑ ‑ 19/52   2/44 ‑
    Ⅲ‑Ⅳ ‑ ‑ 33/52 42/44 ‑
  Tumor grade
    Well-differentiated - - 14/52   7/44 -
    Moderately-differentiated - -   9/52 10/44 -
    Poorly-differentiated - - 29/52 27/44 -
  FN1 (mean ± SD) 69.14±13.29 - 62.41±12.78 71.08±13.19 0.004
  ORM1 (mean ± SD) 157.43±18.26 - 173.64±22.69 221.12±34.60 0.000
  SERPINA1 (mean ± SD) 756.19±244.39 - 685.69±204.59 816.26±245.53 0.021
Metabolomics (n=132)
  No. of patients 41 9 45 37 -
  Age (years) (mean ± SD) 39.61±9.25 42.56±15.44 46.56±10.03 47.41±12.46 -
  Histological type     
    Serous - - 23/45 11/37 -
    Mucinous - -   6/45   4/37 -
    Other - - 14/45 19/37 -
    NA - -   2/45   3/37 -
  FIGO stage     
    Ⅰ‑Ⅱ ‑ ‑ 13/45   3/37 ‑
    Ⅲ‑Ⅳ ‑ ‑ 31/45 32/37 ‑
    NA - -   1/45   2/37 -
  Tumor grade     
    Well-differentiated - -   6/45   3/37 -
    Moderately-differentiated - -   5/45   4/37 -
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KH2PO4 (pH 3.0), 25% v/v ACN (mobile phase A). Peptides 
were eluted with a linear gradient of 0-500 mM KCl (mobile 
phase B: 25% v/v ACN, 10 mM KH2PO4, 500 mM KCl, 
pH 3.0) for 115 min at a flow rate of 0.2 ml/min. Fractions were 
collected at 2-min intervals, and 16 fractions were collected 
from 24.5 to 98.5 min. Each SCX fraction was desalted using 
C18 Spin Columns (The Nest Group, Inc., Southborough, 
MA, USA) following the manufacturer's instructions and 
then vacuum centrifuged to dryness. The peptide fractions 
were separated on a nano-reverse-phase LC system (Tempo™ 
LC MALDI Spotting System; Applied Biosystems), using 
a Magic C18AQ column (150 mm x 200 µm, 3 µm, 200 Å; 
Michrom Bioresources, Inc., Auburn, CA, USA), at a flow rate 
of 2 µl/min. A binary gradient with buffer A (98% H2O, 2% 
ACN, and 0.1% TFA) and buffer B (2% H2O, 98% ACN, and 
0.1% TFA) was employed as the mobile phase. The peptide 
solutions were first loaded for 20 min using buffer A only on 
the pre-column, and the separation occurred over a period 
of 110 min. The elution from the column was mixed in 1:1 
ratio with 5 mg/ml CHCA with a flow rate of 2 µl/min, and 
spotted onto the MALDI plates in a 44x28 spot array format. 
MS and MS/MS analysis was performed on a TOF-TOF 
5800 MALDI platform (Applied Biosystems). MS spectra 
were recorded in the positive-ion reflector mode covering 
700/800-4000 mass-to-charge ratio (m/z) acquiring 1,500 
laser shots per spectrum (30 subspectra of 50 shots). After 
screening of all LC-MALDI sample positions the fragmenta-
tion of automatically selected precursors was performed at a 
collision energy of 2 kV with collision-induced dissociation gas 
(air). Up to 20 of the most intense ion signals per spot po sition, 
characterized by an S/N >45, were selected as precursors for 
MS/MS acquisition.
Table I. Continued.
Clinical characteristics NC BOC PTS PTR P-value
    Poorly-differentiated - - 27/45 20/37 -
    NA - -   7/45 10/37 -
  Primary therapy outcome
    Success - - 22/45 13/37 -
    CR+PR - - 21/45 23/37 -
    SD+PD - -   2/45   1/37 -
    NA     
NC, normal control; BOC, benign ovarian cyst; PTS, platinum‑sensitive; PTR, platinum‑resistant; iTRAQ, isobaric tags for relative and 
absolute quantitation; ELISA, enzyme‑linked immunosorbent assay; NA, not available.
Figure 1. (A) Overall workflow for screening and validation experiments. (B) Comparison of human serum after depletion of the targeted high abundant 
proteins. Samples were separated by 10% SDS‑PAGE and visualized by Coomassie Brilliant Blue staining: lane 1, human crude serum; lane 2, low‑abundant 
proteins. (C) Equal amounts of the depleted sera from NC, PTS, and PTR individuals were loaded in each lane, according to the concentrations determined by 
the BCA kit. NC, normal control; PTS, platinum‑sensitive; PTR, platinum‑resistant.
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Database searches and criteria. Peptide matching, protein 
identification, and relative protein quantification for the 
iTRAQ experiment were performed with ProteinPilot v4.0 
software (Applied Biosystems) in which the paragon search 
Figure 2. (A) Analysis of the 64 differential proteins between PTS and PTR group showing cellular component, molecular function and biological process. 
(B) Hierarchical clustering analysis representation of the altered serum protein profiles identified in PTS and PTR patients using a shotgun quantitative 
proteomic approach. Red, overexpressed genes; green, underexpressed genes. (C) Logarithmic plot of unused score of proteins in PTS vs. PTR pools. Red 
pentagrams, green diamonds and blue triangles denote R/S ratio >1.3-folds, <0.77-folds, and between them, respectively. (D) Biological interaction network 
analysis of proteins that showed differential abundance between PTS and PTR patients. (E‑J) k‑means clustering of differential protein profiles. The cluster 
gene number is labeled in the upper‑left corner of each figure. Each line in the charts represents one differentially expressed protein. The shape of the line 
reveals the trend of differential expressed proteins in four groups. PTS, platinum‑sensitive; PTR, platinum‑resistant.
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Table Ⅱ. Differentially expressed proteins identified by iTRAQ between PTR group compared to PTS group.
Unused Sequence iTRAQ ratio
protein coverage Accession  Gene --------------------------- Expression
score (%) no. Name symbol Species Run 1 Run 2 pattern
  13.01 47.80 P02763 α-1‑acid glycoprotein 1 ORM1a Human 3.32 2.34 Up
    4.56 41.80 P19652 α-1‑acid glycoprotein 2 ORM2a Human - 2.33 Up
    8.52 46.50 D1MGQ2 α-2 globin chain HBA2 Human 1.58 1.56 Up
  23.74 72.70 P02647 Apolipoprotein A‑I APOA1a Human 2.00 1.72 Up
    3.52 68.00 P02652 Apolipoprotein A-Ⅱ APOA2 Human 1.33 - Up
    2.99 23.60 Q13790 Apolipoprotein F APOF Human 1.36 - Up
    2.00 30.00 P08519 Apolipoprotein(a) LPA Human - 1.57 Up
  19.91 35.80 P22792 Carboxypeptidase N subunit 2 CPN2 Human - 1.45 Up
    8.27 30.10 P06276 Cholinesterase BCHEa Human - 1.31 Up
    1.60 25.20 P31146 Coronin‑1A CORO1A Human 1.81 - Up
    1.86 35.30 Q5VVP7 C‑reactive protein, pentraxin‑related CRP Human 3.82 2.46 Up
  17.63 55.50 E9KL23 Epididymis secretory sperm binding SERPINA1a Human 6.02 3.80 Up
   protein Li 44a     
    4.23 44.00 P02675 Fibrinogen β chain FGBa Human 2.42 - Up
111.13 54.60 P02751 Fibronectin FN1 Human 2.52 - Up
  16.43 55.20 O75636 Ficolin‑3 FCN3 Human - 1.37 Up
  63.09 79.10 P00738 Haptoglobin HPa Human 2.71 2.59 Up
  18.65 84.40 D9YZU5 Hemoglobin, β HBBa Human 1.76 1.46 Up
    1.46 14.30 P01880 Ig δ chain C region IGHD Human - 2.54 Up
    2.03 39.30 P01860 Ig γ‑3 chain C region IGHG3 Human 1.36 1.47 Up
    3.89 51.90 P0CG05 Ig λ‑2 chain C regions IGLC2 Human - 1.72 Up
  13.88 41.20 P01871 Ig μ chain C region IGHM Human - 1.37 Up
224.13 70.60 P02751-8 Isoform 8 of fibronectin FN1a Human - 2.35 Up
    1.35 43.70 Q9BWP8-9 Isoform 9 of collectin‑11 COLEC11 Human 1.34 - Up
  25.71 70.90 P02750 Leucine‑rich α-2‑glycoprotein LRG1 Human - 1.55 Up
    2.43 19.00 Q6Q3G8 Lysosomal‑associated membrane LAMP2a Human 1.81 - Up
   protein 2, isoform CRA_b     
    2.23 6.70 Q6UXB8 Peptidase inhibitor 16 PI16 Human - 1.30 Up
    2.56 47.40 P06702 Protein S100A9 S100A9a Human 1.36 - Up
  94.91 82.10 P02787 Serotransferrin TFa Human 1.63 1.58 Up
  75.06 73.60 P02768 Serum albumin ALBa Human - 1.50 Up
    3.27 70.00 E9PR14 Serum amyloid A protein SAA2 Human 4.57 2.63 Up
    2.04 17.80 E7ES66 Uncharacterized protein GP1BA Human 1.50 - Up
    5.51 37.80 B4E1D3 Uncharacterized protein FGB Human - 2.46 Up
    2.01 20.40 C9JC84 Uncharacterized protein FGG Human - 2.60 Up
    8.99 21.90 P04275 von Willebrand factor VWFa Human - 1.33 Up
499.38 71.20 P04114 Apolipoprotein B‑100 APOBa Human - 0.74 Down
    3.82 61.50 B2R526 Apolipoprotein C‑I APOC1 Human 0.63 - Down
    6.00 65.40 P02655 Apolipoprotein C-Ⅱ APOC2 Human 0.62 0.68 Down
    7.18 61.50 B0YIW2 Apolipoprotein C-Ⅲ variant 1 APOC3a Human 0.60 0.58 Down
  23.95 77.30 P02649 Apolipoprotein E APOEa Human - 0.60 Down
    8.96 43.20 Q96KN2 β‑Ala‑His dipeptidase CNDP1 Human - 0.71 Down
    2.01 30.60 P49913 Cathelicidin antimicrobial peptide CAMP Human 0.71 - Down
    4.00 21.70 P00488 Coagulation factor ⅩⅢ A chain F13A1a Human 0.75 0.67 Down
    2.60 21.90 Q12860 Contactin‑1 CNTN1a Human 0.72 - Down
    2.10 22.60 P22352 Glutathione peroxidase 3 GPX3a Human - 0.76 Down
    5.52 43.20 Q1KLZ0 HCG15971, isoform CRA_a PS1TP5BP1a Human 0.62 0.39 Down
  50.43 70.10 P05546 Heparin cofactor Ⅱ SERPIND1 Human - 0.76 Down
    3.78 31.50 P26927 Hepatocyte growth factor‑like protein MST1 Human 0.75 - Down
110.79 52.90 P19823 Inter‑α‑trypsin inhibitor ITIH2a Human - 0.77 Down
   heavy chain H2     
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algorithm was applied. MS/MS spectra were searched against 
the UniProt/Swiss-Prot database for species of Homo sapiens. 
The database was searched using the following parameters: 
trypsin was used as the digestion agent, MMTS as a fixed 
modification of cysteine, thorough as search effort, and 
biological modification as the ID focus. Identifications of 
proteins were only accepted with a ‘local false discovery 
rate (FDR)’ estimation of ≤5% and an unused ProtScore ≥1.3 
(>95% CI). In addition, proteins were considered for further 
statistical analysis when meet the following standards: one or 
more unique peptides with 95% confidence had to be identi-
fied; proteins were considered up‑ or downregulated when 
their fold changes were >1.3 or <0.77. The results obtained 
from ProteinPilot were exported to Microsoft Excel for 
manual interpretation. The protein lists from the two iTRAQ 
experiments (run 1 and 2; Table Ⅱ) were merged with ratios 
calculated to the reference pool.
Western blot t ing. To confi rm the identity of the 
proteins dis covered by iTRAQ, western blotting was 
performed (Fig. 3A‑E). Briefly, equal volumes of non-depleted 
serum from NC, PTS and PTR individuals (n=9 per group) 
were electrophoretically separated by 10% SDS-PAGE 
and transferred to a 0.45-mm polyvinylidene f luoride 
membranes (EMD Millipore) using a Bio-Rad wet transfer 
apparatus. Anti-human ORM1 (2 µg/ml), FN1 (1:1,000 dilu-
tion), SERPINA1 (1:1,000) and GPX3 (1:500) antibodies were 
from R&D Systems, Inc. (cat. no. MAB3694), Sigma (cat. 
no. F3648), OriGene Technologies, Inc., (cat. no. TA500376) 
and Abcam (cat. no. ab27325). Secondary antibodies 
were DyLight 680 anti-mouse (cat. no. 072-06-18-06, 
1:5,000 dilution; KPL, Inc.) and IRDye 680RD donkey 
anti‑rabbit (cat. no. 926‑32223, 1:5,000 dilution; LI‑COR 
Biosciences). Membranes were blocked with 5% skim milk 
in phosphate-buffered saline (PBS) with 0.1% Tween-20 
for 2 h at room temperature. The concentration of primary 
and secondary antibodies was consistent as recommended 
in the instructions. Then membranes were incubated with 
primary antibodies overnight at 4˚C, followed by fluorescent 
secondary antibodies (1:5,000) for 1 h at ambient tempera-
ture. After washing three times in PBST, proteins were 
detected with Odyssey infrared imaging system (LI-COR 
Biosciences, Lincoln, NE, USA) following the manufac-
turer's instructions.
ELISA. Based on the iTRAQ and western blotting findings 
above we selected four targets, SERPINA1, ORM1, GPX3 and 
FN1, the protein markers potentially associated with PTR, for 
the validation using ELISA method. ORM1, FN1, SERPINA1 
ELISA kits were obtained from and utilized according to the 
manufacture's instructions. ORM1 and FN1 serum samples 
were diluted 100-fold, and SERPINA1 serum samples were 
diluted 50-fold. All samples and standards were tested in 
triplicate. Absorbance was determined using Power Scan 4 
multiplex microplate reader (DS Pharma Biomedical Co. 
Ltd., Osaka, Japan) and analysis of results was conducted by 
SPSS 16.0 software.
Statistical analysis. Statistical analyses were performed 
with SPSS 16.0 software (SPSS, Inc., Chicago, IL, USA). 
A comparative analysis of multiple groups was analyzed 
by one-way ANOVA or Kruskal-Wallis test and multiple 
Table Ⅱ. Continued.
Unused Sequence iTRAQ ratio
protein coverage Accession  Gene ----------------------------- Expression
score (%) no. Name symbol Species Run 1 Run 2 pattern
    1.66 14.60 Q9NPH3 Interleukin‑1 receptor accessory protein IL1RAP Human 0.52 - Down
    2.00 36.20 O14791-2 Isoform 2 of apolipoprotein L1 APOL1 Human - 0.76 Down
    4.00 19.20 P16070-5 Isoform 5 of CD44 antigen CD44a Human 0.74 - Down
204.25 80.80 B7ZKJ8 ITIH4 protein ITIH4 Human - 0.59 Down
  44.35 54.80 P01042 Kininogen‑1 KNG1a Human 0.77 - Down
    8.29 43.20 Q5SQS3 Mannan‑binding lectin MBL2a Human 0.69 0.59 Down
    1.33 11.80 P04180 Phosphatidylcholine‑sterol LCAT Human 0.64 - Down
   acyltransferase     
    2.00 13.60 Q53Y44 Profilin PFN1 Human - 0.68 Down
  99.83 76.50 P00734 Prothrombin F2a Human - 0.65 Down
  21.20 60.10 P02743 Serum amyloid P component APCS Human - 0.58 Down
    9.43 27.90 P27169 Serum paraoxonase/arylesterase 1 PON1a Human 0.66 - Down
    2.00 17.70 O00391 Sulfhydryl oxidase 1 QSOX1a Human - 0.37 Down
    2.00 23.10 D3DUS9 Triosephosphate isomerase TPI1a Human - 0.70 Down
    3.05 51.60 P67936 Tropomyosin α‑4 chain TPM4 Human - 0.68 Down
    6.31 26.60 A6NHF2 Uncharacterized protein BTD Human 0.41 - Down
    2.00 21.50 E7EX29 Uncharacterized protein YWHAZa Human 0.75 - Down
aThe peptides identified with 95% confidence. iTRAQ, isobaric tags for relative and absolute quantitation; PTR, platinum‑resistant; PTS, platinum‑ 
sensitive.
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comparisons were performed with the least significant differ-
ence test. Results are presented as means ± SD. ROC curves 
were used to determine the diagnostic value of the markers. 
P<0.05 was considered statistically significant.
Metabolical analysis
Serum sample preparation. Prior to serum preparation, samples 
were thawed on ice for 1 h. A total of 200 µl of serum (stored 
at ‑80˚C) was resuspended with 800 µl cold CAN (stored at 
Figure 3. (A-D) Western blotting of SERPINA1, ORM1, GPX3 and FN1 protein expressions in human serum. Western blotting was carried out using anti-
bodies against SERPINA1, ORM1, GPX3 and FN1. Consistent with the proteomic results, the expressions of SERPINA1, ORM1 and FN1 were significantly 
upregulated (p<0.05), whereas, GPX3 protein expression was significantly downregulated (p<0.05) in PTR group, compared to the PTS group. (E) The overall 
protein profile of the NC, PTS and PTR groups. The gel was stained with Coomassie Brilliant Blue to ensure equal loadings during immunoblotting analysis. 
The expression levels of the four differential proteins were normalized based on the Coomassie Brilliant Blue staining. *P<0.05. ROC curve analysis using the 
ELISA profile of the (F) SERPINA1, (G) ORM1 and (H) FN1 for the 129 sera analyzed. SPSS software was used to construct ROC curves and to calculate the 
AUC. The solid lines in the ROC curves represent the plot of 1‑specificity vs. sensitivity. Histogram was used to elucidate the profile of ELISA. Mean ± SD 
was used to express protein level. *P<0.05, **p<0.01. (I) Clinical diagnostic performance of the three proteins in PTR and PTS groups. PTR, platinum‑resistant; 
PTS, platinum‑sensitive; NC, normal control; ROC, receiver operating characteristic; ELISA, enzyme‑linked immunosorbent assay; AUC, area under the 
curve.
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‑20˚C) mixed thoroughly, and precipitated on ice for 2 h. The 
samples were centrifuged at 4˚C and 12,000 x g for 15 min. The 
supernatant was then transferred to a new tube. Subsequently, 
serums were lyophilized for 24 h using a freeze dryer (Beijing 
Songyuan Huaxing Biotechnology Co., Ltd., Beijing, China). 
Methanol (200 µl) was added to lyophilized samples, vortexed, 
sonicated for 5 min, and centrifuged (12,000 x g, 4˚C, 5 min). 
The supernatant (150 µl) was collected for further analysis.
Metabolic signature via LC‑MS. LC-MS analysis was performed 
using Agilent HPLC (1290 series) fitted with a Zorbax Rx‑C8 
column (5 µm, 150x2.1 mm; Agilent Technologies, Inc.) and 
coupled to a Bruker Daltonics' micrOTOF‑Q Ⅱ high‑resolution 
mass spectrometer. The flow rate was 0.25 ml/min, injection 
volume 5 µl and column temperature 30˚C. The mobile phase 
was consisted of solvent A (0.1% formic acid, 99.9% water) 
and solvent B (0.1% formic acid, 99.9% ACN). HPLC condi-
tions were 15% solvent B changing linearly to 40% solvent B 
over 5 min, to 80% solvent B over 10 min, 80% solvent B over 
5 min, to 90% solvent B over 5 min, and then 90% solvent B 
over 15 min. Finally, mobile phase constituents reverted to 
starting conditions for 5 min re-equilibration. Total analysis 
time was 45 min. Mass spectral analysis was operated on a 
micrOTOF‑Q Ⅱ high‑resolution mass spectrometer (Bruker 
Daltonics) linked to an Agilent HPLC (1290 series) by HyStar 
software (Bruker Daltonics). Electrospray ionization (ESI) 
(positive ion mode) was used to identify the molecular ion mass 
[M+H]. Source parameters are: ESI capillary voltage, 4,500 V; 
nebulizing gas pressure, 1 bar; drying gas flow, 6 l/min; and 
drying gas temperature, 220˚C. Data were acquired in a mass 
range of 50-1,500 m/z.
Data analysis. Following LC-MS, raw MS data were converted 
into a matrix that is compatible with multivariate statistical 
analysis and interpretation by using an in-house set of tools, 
such as the Compass software package (Bruker Daltonics). 
Signals obtained from each sample in the chromatogram were 
segmented into a series of regions characterized by retention 
time and m/z using the Compass software, furthermore, the 
theoretical m/z values were compared with the experimental 
values from MS signals. Based on the exact m/z, elemental 
formulas were generated using the DataAnalysis soft-
ware (Bruker Daltonics). C, H, N, O, P and S were the elements 
of the formulas. The lists of generated formulas were searched 
against the METLIN database (https://metlin.scripps.edu/) to 
identify compounds. Principal component analysis (PCA) was 
then operated utilizing Profile Analysis software (Compass 
software package; Bruker Daltonics).
Results
Proteomic analysis
Serum proteomic data analysis. To enhance the detection 
of the lower abundance proteins, most of the 14 abundant 
proteins were removed in equal volumes from each sample. 
Technical replicate samples were used to increase the reli-
ability of the iTRAQ technique for relative quantitation. The 
relative expression levels, statistical parameters and the peptide 
information of identified proteins for each pool were obtained 
from two (replicate) peptide spectra data as described above. 
Subsequently, all the identified proteins were filtered with 
manually selected filter exclusion parameters. Thus, in the 
first iTRAQ data set (run 1), identification of 197 proteins was 
made. Similarly, 184 proteins were discovered in the second 
iTRAQ data set (run 2). The proteins identified from the two 
iTRAQ data sets were subsequently combined, and a total of 
248 unique proteins were identified and quantified. Proteins 
were considered up- or downregulated when their ratios were 
>1.3 or <0.77 (Fig. 2C). Therefore 64 proteins were screened 
out as candidate biomarkers in one or two separate experiments 
as differentially expressed proteins between PTS and PTR 
sets: 33 of which were increased (PTR/PTS >1.3) and 31 were 
decreased (PTR/PTS <0.77). Candidate biomarkers selected 
by these criteria are summarized in Table Ⅱ. For better under-
standing of the data structure in our experiment, a clustering 
algorithm for grouping proteins was required (Fig. 2B), and 
k-means clustering approach was then performed to group the 
data based on the degree of similarity between the PTS and 
PTR group. The different trends of identified proteins during 
PTS and PTR can be grouped into six subsets with a similar 
expression pattern (Fig. 2E). In the first subset, most of the 
20 proteins were upregulated in a stepwise way in NC, BOC, 
PTS and PTR groups. Most are extracellular proteins involved 
in cell adhesion, cell communication and immune system 
process. The trend of these proteins differentially expressed in 
PTS and PTR groups were of interest as these could provide 
leads for potentially useful biomarkers of platinum status. In 
the second set, all the 10 proteins were specifically increased 
in PTS group and are therefore interesting candidates for EOC 
diagnosis or prognostic studies.
Gene ontology analysis. Data analysis of 64 unique proteins 
identified by two iTRAQ experiments was performed using the 
Blast2GO database (http://www.blast2go.com/b2ghome) and 
Web Gene Ontology Annotation Plot (WEGO: http://wego.
genomics.org.cn/cgi-bin/wego/index.pl) to class each protein 
into its respective cellular components, molecular function and 
biological process (Fig. 2A). For the 64 differential proteins, 
the subcellular distributions were enriched mainly in extracel-
lular region (90.6 and 78.1%) (the two numbers represent the 
upregulated and downregulated proteins proportion of the 
total, respectively), which imply that most of these proteins are 
secretary proteins. According to GO molecular function anal-
ysis, the top three common functional annotations were binding 
(87.5 and 93.8%), catalytic (28.1 and 56.3%), and enzyme 
regulator (25 and 31.3%). Most of the differential proteins were 
involved in biological regulation (90.6 and 84.4%), response to 
stimulus (81.3 and 87.5%), and pigmentation (84.4 and 71.9%). To 
clearly show the expression trend of differential proteins during 
cancer progress, k-means clustering method was used to classify 
the 64 protein. The results are shown in Fig. 2E. For further 
text mining, PANTHER Classification System (http://www.
pantherdb.org/) was used to carry out the GO analysis. During 
tumor progression, 20 proteins were upregulated gradually in 
cluster A and most of these members participated in immune 
system process, cell adhesion, and cell communication, which 
would make sense in connection with drug resistance.
Pathway and biological interaction network analyses. 
Enrichment analysis of associated diseases and drugs was 
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performed for the differentially expressed proteins that 
met our thresholds (fold, rank) using the IPAD browser 
(http://bioinfo.hsc.unt.edu/IPAD/) tools. Results of associated 
diseases and drug analysis showed that 30 proteins (14 upregu-
lated, 16 downregulated) among them were significantly 
associated with EOC (indicated as pentagrams in Table Ⅱ) 
and GPX3 was associated with cisplatin. In addition, DAVID 
Bioinformatics Resources 6.7 (http://david.abcc.ncifcrf.
gov/home.jsp) was used to investigate possible interactions 
between the 30 proteins associated with EOC, which revealed 
that the differential proteins were significantly enriched in 
complement and coagulation cascades and ECM-receptor 
interaction. To model the signaling network potentially 
affected in the context of platinum status, the 17 focus proteins 
with fold changes between PTS and PTR group >1.5 were 
then subjected to network analysis using STRING software 
(http://string‑db.org/). The network analysis identified ALB, 
APOA1, SERPINA1, FN1, ORM1 and TF as the major molecules 
affected in PTR patients (Fig. 2D). Candidate proteins with 
the most extreme deviation from the NC, BOC, PTS groups, 
including SERPINA1 (3.8-fold increased), ORM1 (3.32-fold 
increased), FN1 (2.35-fold increased) and cisplatin-associated 
GPX3 (1.35‑fold decreased), were commonly identified in two 
iTRAQ experiments, and chosen for further analyses.
Co‑occurrence analysis with COREMINE. COREMINE 
was used to performe co-occurrence analysis based on 
literature. The 64 differentially expressed proteins and the 
following list of keywords were used to interrogate the tools: 
drug resistance, neoplasm; drug resistance; drug resistance, 
multiple. In order to restrict the number of proteins poten-
tially associated with drug resistance or MDR, p<0.01 was 
considered statistically significant. The cumulative frequency 
top 50 protein lists out of connected proteins, which showed 
a p<0.01 and the 64 differentially expressed proteins were 
compared to look for the degree of overlap. Finally, proteomic 
and co-occurrence analysis shared the following 11 proteins: 
ALB, CRP, FN1, S100A8, TF, VWF, APOC2, APOE, CAT, 
CD44, F2.
Western blotting. A total of 27 serum samples, composing 
9 from NC group, 9 from PTS group, and 9 from PTR group, 
were subjected to western blotting against SERPINA1, ORM1, 
GPX3 and FN1. These proteins were selected for western 
blotting primarily the following factors: big fold changes of 
differential expression, correlation with cancer/drug resistance 
from a literature-based text mining, the expression trend in 
four pools and the availability of commercial antibodies. Our 
results indicated that three of the four candidates have similar 
trends with the proteomic results (SERPINA1, ORM1, FN1) 
in the serum of PTR cases, compared to PTS cases, which 
implied the credibility of proteomic analysis (Fig. 3A-D). 
One-way ANONA was applied to calculate means ± SD from 
each group along with p-values.
Clinical relevance of SERPINA1, ORM1, GPX3 and FN1. In 
the initial experiment 10 NC, 10 PTS and 10 PTR samples 
were used to validate the expression levels of SERPINA1, 
ORM1, GPX3 and FN1. The results illustrated that statistical 
significant difference between PTS and PTR was seen for 
SERPINA1, ORM1 and FN1, but not GPX3 (data not shown). 
However, the expression of GPX3, which was observed to 
be downregulated (FC=1.35) in proteomic analysis, was not 
significantly different (p>0.05) by ELISA. Consequently, we 
carried a full validation study for SERPINA1, ORM1 and 
FN1, using the entire 129 samples collected (data are shown 
in Table I). Consistent with the iTRAQ results in the previous 
experiment, relative quantitation of SERPINA1, ORM1 and 
FN1 (Fig. 3F-I) between PTS 52 samples and PTR 44 samples 
were all found to be significantly upregulated (p<0.05). 
Likewise, to further evaluate the diagnostic significance of 
these three proteins, a ROC curve analysis was constructed for 
each protein by plotting sensitivity vs. specificity. The overall 
predictive accuracy of each protein was reflected by the area 
under the ROC curve (AUC), a commonly used indicator for 
estimating the diagnostic efficacy of a potential biomarker. 
FN1 and SERPINA1 with ROC areas of 0.679 and 0.666, 
respectively, suggest that their use as a biomarker may not be 
reliable. Unlike the FN1 and SERPINA1, the AUC for ORM1 
was 0.91 and its sensitivity and specificity for predicting PTR 
was 71 and 97.4%, respectively, which could clearly separate 
the PTS patients from the PTR individuals. These results high-
light a potential role for ORM1 in the response to platinum 
therapy.
Metabolic analysis. A total of 25,800 metabolic features 
was observed in our study. Data of identified compounds 
were subjected to t-test analysis to identify significant 
metabolic patters and variations. Compounds having p<0.01 
and fold‑change >2 were considered as statistically signifi-
cant. PCA and multivariate statistics were then applied to 
identify key PTR-associated metabolic perturbations in 
PTR compared to PTS. Unsupervised PCA of the resultant 
data showed clear metabolic separation of PTR from PTS 
along the first principal component, and clear distinctions 
of EOC (PTR and PTS) from healthy individuals along 
the second principal component (Fig. 4A). The BOC sera 
were not obviously grouped because of their limited sample 
size. PCA loading plots (Fig. 4B) provided six metabolite 
features contributing to the separation of groups along 
PC1 and PC2. Six known compounds were identified using 
NMR based on database (Table Ⅲ). The levels of the six 
potential biomarkers in blood from PTR, PTS and NC 
group were determined by LC-MS/MS. Compared to PTS, 
PTR exhibit a specific metabolic trait characterized by 
decreased levels of calycanthidine and increased levels of 
1‑monopalmitin, ricinoleic acid methl ester, polyoxyethylene 
(600)mono‑ricinoleate/glycidyl stearate. Furthermore, the 
concentration of dodemorph was higher and of C16 sphin‑
ganine was lower in the EOC compared to NC (Table Ⅲ). 
ROC curve was used to calculate sensitivity and specificity 
of the four biomarkers for PTR compared with PTS. The 
AUC for 1‑monopalmitin, ricinoleic acid methyl ester, poly‑
oxyethylene (600)mono‑ricinoleate and calycanthidine was 
0.892, 0.900, 0.883 and 0.109, respectively, and their sensi-
tivity and specificity for predicting PTR were 83.8 and 75%; 
81.1 and 86.4%; 83.8 and 75%; 90.9 and 73%, respectively, 
which could clearly separate the PTS patients from the PTR 
individuals. The combinational four biomarkers achieved 
an AUC value (AUC=0.925) while the statistical analysis 
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provided 86.5% sensitivity and 81.8% specificity for the 
prediction of PTR (Fig. 5).
Discussion
Cisplatin is one of chemotherapeutical agents commonly 
used to treat EOC, which causes DNA damage via forming 
inter- and/or intrastrand DNA adduct lesions and eventu-
ally cytotoxicity. However, the benefits of chemotherapy 
can be attenuated because of the emergence of platinum 
resistance. To eradicate the mechanisms of platinum resis-
tance in EOC is a difficult task. The recent development of 
proteomic approaches applied to investigate drug-resistance 
mechanisms has greatly helped in addressing these issues. 
Comparative proteomic approach is a powerful tool, which 
might help to guide future research and cross validation of 
various proteomic profiling with a high throughput. In our 
experiment, a panel of 64 different proteins that have altered 
expression in PTR patients were compared to the parental PTS 
group using a shotgun quantitative proteomics approach, and 
four of these proteins were confirmed with western blotting 
and ELISA. The results of serum FN1, SERPINA1, GPX3 
and ORM1 from 2D-LC-MS/MS analysis were validated in 
a 139 cohort using a different methodology. Western blotting 
and ELISA confirmed that the serum level of FN1, SERPINA1 
and ORM1 was upregulated in PTR group, which indicated 
that the FN1, SERPINA1 and ORM1 serum levels might be a 
tool for screening and diagnosis of PTR. However, it should 
be noted that although the change in direction (up- or down-
regulated) of GPX3 detected by western blotting between 
PTS and PTR group was consistent with iTRAQ, the changes 
measured by ELISA assay in 43 patients was not statisti-
cally significant (p>0.05). The differences in fold change 
determined by iTRAQ, western blotting and ELISA can be 
attributed to methodological factors such as the use of isobaric 
tags and/or differences inherent in the technical method. ROC 
curve analysis was applied to find the cut‑off value of serum 
FN1, SERPINA1 and ORM1 to discriminate between PTS and 
PTR group. The sensitivity and specificity were calculated. 
ROC curves show, ORM1 with 71% sensitivity and 97.4% 
specificity could give a higher accuracy (Fig. 3). However, FN1 
and SERPINA1 were not reliable for clinical diagnosis because 
of low sensitivity and specificity. Our comprehensive study of 
proteomics led to the possibility that monitoring the level of 
Table Ⅲ. Relevant analytical data for the metabolites identified in PTR, PTS, BOC and NC groups.
Retention   Error  Molecular  CAS/ 
time (min) Adduct m/z (mDa) σ value formula Trend PubChem Possible metabolite
19.9 [M+H] 282.2807 -1.5 0.0064 C18H35NO Up (EOC/NC) 1593-77-7 Dodemorph
  9.4 [M+H] 274.2777 -3.6 0.0329 C16H35NO2 Down (EOC/NC) 4266342 C16 sphinganine
16.9 [M+H] 313.2775 -3.9 0.0334 C19H36O3 Up (PTR/PTS) 141-24-2 Ricinoleic acid methyl ester
16.8 [M+H] 331.2871 -2.8 0.006 C19H38O3 Up (PTR/PTS) 542-44-9 1‑Monopalmitin
19.2 [M+H] 341.3071 -2.1 0.0067 C21H40O3 Up (PTR/PTS) 977137-78-2 Polyoxyethylene 
        (600)mono‑ricinoleate
19.2 [M+H] 341.3071 -2.1 0.0067 C21H40O3 Up (PTR/PTS) 7460-84-6 Glycidyl stearate
19.9 [M+H] 361.2419 -4.6 0.0235 C23H28N4 Down (PTR/PTS) 5516-85-8 Calycanthidine
PTR, platinum‑resistant; PTS, platinum‑sensitive; BOC, benign ovarian cyst; NC, normal control; m/z, mass‑to‑charge ratio; EOC, epithelial ovarian 
cancer.
Figure 4. Multivariate statistical analysis. (A) PCA score plots. Blue rings, PTS; red triangles, PTR; blue plus, BOC; green multiplication, NC. (B) PCA 
loading plots. Selecting compounds far away from the center were assumed to have a greater contribution to the classification of PTS, PTR, BOC, and NC are 
numbered. PCA, principal component analysis; PTS, platinum‑sensitive; PTR, platinum‑resistant; BOC, benign ovarian cyst; NC, normal control.
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serum ORM1 could be clinically useful for the screening and 
diagnosis of PTR patients.
α‑1‑antitrypsin (SERPINA1) is an inhibitor of serine prote-
ases principally secreted by hepatocytes, but also by monocytes, 
neutrophils, macrophages and alveolar epithelial cells, and 
plays a critical role in modulating host immunity, inhibiting 
T lymphocyte-mediated antitumor function and thereby accel-
erated tumor proliferation, and metastasis (3-5). Moreover, 
there have been numerous studies documenting a link between 
SERPINA1 and various cancers, although for most the mecha-
nism for the linkage is unclear. Giving the expression levels of 
SERPINA1 in rat bladder tumor tissues were 2.5-fold higher 
than those in normal bladder tissues using two-dimensional 
difference gel electrophoresis (2D-DIGE) (6). Similar conclu-
sions were also obtained in pancreatic tumors, hepatocellular 
carcinoma, non-small cell lung cancer, gastric cancer in gastric 
juice, prostate cancer patients and malignancy in insulinomas. 
Much attention has been focused on the role of SERPINA1 
as a tumor suppressor, but no report has shown directly the 
relation between SERPINA1 and chemotherapy drugs. In our 
study, the contribution of SERPINA1 to drug resistance was 
implicated in human serum samples. SERPINA1 shows one 
of the largest fold increases (3.8-fold increased) in protein 
expression level in PTR cohort compared with PTS cohort 
(p<0.05). Nevertheless, our data are in good agreement with 
prior studies elicited above, but disagree with the results of 
Normandin et al (7).
Fibronectin is a glycoprotein that is involved in cell adhe-
sion, signal transduction and migration processes including 
embryogenesis, wound healing, blood coagulation, host 
defense, and metastasis, especially possibly suppression of 
apoptosis (8-10). There have been many reports on the relation 
between FN1 and human tumors. Similar thesis reported that 
fibronectin was involved in Ras, Erk, Akt and ECM pathways 
and mediate various signals such as cancer cell adhesion, 
growth migration and invasion (11,12). Akiyama et al showed 
Figure 5. (A-E) The ROC curves of the candidate biomarkers. (F) Clinical diagnostic performance of the four metabolites in PTR and PTS groups. ROC, 
receiver operating characteristic; PTR, platinum‑resistant; PTS, platinum‑sensitive.
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that FN1 played a causal role in tumor neovascularization and 
metastasis (13). In addition, a recent study found that FN1 is 
one of the key genes in regulating SOX2 cell migration, inva-
sion, colony formation and drug resistance in ovarian cancer 
cells (14-16). Qian et al also indicated that FN1 is targeted 
by let-7g to promote mammary carcinoma cell migration and 
invasion via p44/42 MAPK and MMPs (17). FN1 was also 
suggested as a marker for renal cell carcinoma aggressive-
ness (18,19). Moreover, FN1 was shown to be a direct target 
gene for miR-1 and miR-200. While miR-1 may play a role 
as a tumor suppressor gene in laryngeal carcinoma. Similarly, 
miR-200 is crucial for the maintenance of epithelial identity, 
behavior, and sensitivity to chemotherapy in ovarian cancer 
cell line (20,21), which confirmed our previous observation 
by miRNA microarrays with samples obtained from the same 
patients as this study (22). All these findings suggest that a 
functional relation is present between FN1 and platinum 
response, which supports our data in EOC.
As a member of guutathione peroxidases, GPX3 is located 
in 5q23 and has critical roles in the detoxification of hydrogen 
peroxide and other oxygen-free radicals. Previous studies have 
demonstrated that GPX3 had a broader downregulated pattern 
in a variety of cancers, such as ovarian, cervical, thyroid, head 
and neck, lung, colorectal, gastric, gallbladder, breast, and 
esophageal cancers than in healthy controls. These reports 
suggest that GPX3 contains a tumor-suppressor function. The 
mechanisms involved in mediating the GPX3 tumor-suppressor 
function are mainly due to promoter hypermethylation (23), 
the downregulation of c-Met expression (24,25), and the role 
of antioxidant enzymes which are involved in reactive oxygen 
species (ROS) metabolism. As a messenger molecule, ROS 
might increase cancer cell proliferation, genetic mutations, 
instability, and thereby invasion and angiogenesis (26). In 
addition, ROS also mediates the induction of tumor cell death 
via many chemotherapeutic agents such as platinum (27). 
Although the researchers failed to measure the serum concen-
tration of GPX3, this statement is supported by our results. 
However, GPX3 is identified to be highly expressed in clear 
cell adenocarcinoma compared to control tissues at a DNA, 
mRNA and protein level on cell lines and clinical samples 
of ovarian clear cell adenocarcinoma (28,29). Although 
the molecular biological mechanism is not clarified, these 
results might indicate that GPX3 activity is tumor‑specific. 
In our present study, GPX3 was shown to be downregulated 
in PTR group compared with PTS group, which confirmed 
the previous results, but the exact mechanism, in response to 
anticancer drugs remains to be further understood.
The α‑1‑acid glycoprotein primarily synthesized by the 
liver is an acute-phase reactant with immunomodulatory and 
immunosuppressive properties (30) and its serum levels are 
increased by inflammation, stress, and chronic disease such 
as cancer (31). Two main biological functions were involved 
in α‑1‑acid glycoprotein, binding and transporting of endog-
enous substances or drugs, and a strong immunomodulatory 
function. Previous investigations in patients with carcinoma 
of the breast, lung, ovary and endometrium have suggested 
that serum ORM1 concentrations were increased two times 
higher than that in healthy individuals, and ORM1 might act 
as blocking agent protecting tumor cells against immuno-
logical attack, thereby contributing to the ʻimmune escapeʼ 
of the tumor (32,33). ORM1 can also interfere with cytokine 
function by inducing the secretion of soluble TNFα receptor 
and IL-1, -6 and -12 receptor antagonist (30,34). Although 
the mechanisms by which ORM1 mediates its functions are 
not fully understood, ORM1 has been shown to bind to the 
chemokine receptor CCR5 in macrophages, the asialogly-
coprotein receptor in hepatocytes, the surface lectin-like 
receptor Siglec‑5 in neutrophils and can also modulate 
TNFα-induced phosphorylation of p38 MAPK, MEK1/2, 
c-Jun N-terminal kinase which is required for angiogenesis 
in macrophages (35-39), but not VEGF-induced signaling. In 
addition, ORM1 has been shown to enhance endothelial cell 
migration and capillary tube formation in vitro (40). Moreover, 
several reports suggested that the serum levels of α‑1‑acid 
glycoprotein influenced the pharmacokinetics (PK)/pharma-
codynamics (PD) of chemotherapy drugs such as docetaxel, 
PTX and imatinib (41-44). As these reports remarked, α‑1‑acid 
glycoprotein may function as a carrier of PTX from the serum 
into the liver via the α‑1‑acid glycoprotein receptors, and 
this might result in the enhancement of the PTX metabolism. 
Although ORM1 has been reported to be associated with 
cancers or metabolisms of chemotherapy drugs according to 
previous reports, no studies have underlined the importance of 
ORM1 in cisplatin resistance in PTR patients, and this is the 
first time that ORM1 was identified as an important biomarker 
of response to cisplatin-based chemotherapy. The mechanism 
of this phenomenon may be attributed to the PK/PD changes 
of cisplatin, however, further studies will be required to fully 
understand ORM1 functional roles in drug resistance.
In the present study, we undertook a non-destructive 
metabolomic technique (HPLC‑micrOTOF‑Q Ⅱ MS/MS) to 
investigate the metabolic traits. All the six metabolites in our 
experiment were identified as fatty acid or derivatives. Profiling 
of metabolomics elucidated changes in the levels of fatty acid 
metabolism, which confirmed our previous observations 
by proteome approach and conclusions of many addressed 
articles on chemotherapeutic resistance and metabolism, and 
served as an insightful reference to the mechanism research 
of drug resistance. Fatty acid synthese (FASN) providing 
proliferating cancer cell lipids for membrane biogenesis was 
assumed to have metabolic characteristics of cancel cells (45). 
Expression level of FASN is significantly upregulated in kinds 
of neoplasm and correlates with poor prognosis, but in a health 
individual is very low even undetectable, suggesting that 
FASN serves as a metabolic oncogene (46). Fatty acids were 
used by proliferating tumor cells for membrane assembly, lipid 
modifications of proteins, and as an efficient source of energy, 
all are required to sustain neoplasm growth and survival (47). 
Furthermore, it is shown that FASN is overexpressed in 
drug-resistant breast neoplasm cell line (MCF7/AdVp3000), 
and that reducing the expression of FASN increased the drug 
sensitivity in MCF7 and MDA-MB-468 (breast cancer cell 
lines) (48). Analogously, FASN was reported to be associated 
with acquired trastuzumab/docetaxel/5‑fluorouracil resistance 
in breast cancer or radiation and gemcitabine in pancreatic 
neoplasm. FASN also played an active role in chemotherapy 
resistance of HER-2/neu-induced breast neoplasm. FASN not 
only played a key role in acquired resistant phenotype but 
also in inherent resistant phenotype in hepatocellular carci-
noma (49). Roodhart et al identified two platinum‑induced 
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polyunsaturated fatty acids which induce resistance to chemo-
therapeutic drugs. When the central enzymes associated with 
the production of polyunsaturated fatty acids were blocked, 
the mesenchymal stem cells induced resistance which was 
prevented (50). All the above further confirmed the metabo-
lism abnormality of fatty acid is induced by PTR.
In conclusion, we identified a panel of new ovarian epithe-
lial cancer serum protein biomarkers, which have an indicator 
value for platinum status and allow patients who have a high 
chance of being resistant to cisplatin-based chemotherapy to 
receive an alternative therapy. Although thousands of metabo-
lites were identified, links were weak and annotated only a 
small proportion of the total analytes. In further studies, the 
role of these differentially proteins or compounds in cisplatin 
resistance needs to be validated on a large scale to evaluate the 
clinical benefit of using these candidate biomarkers for diag-
nosis or prognosis analyses. The contribution of the identified 
biomarkers in cisplatin resistance should also be explored to 
help understand and design chemosensitizing agents. In addi-
tion, our study demonstrated that metabolomics and proteomics 
could validate one another partially and their combination 
could better elucidate the mechanism of drug resistance and 
provide candidate molecular targets for personalizing thera-
peutic interventions and treatment efficacy monitoring.
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